Over the past decades, a frequent co-morbidity of cerebrovascular pathology and
Alzheimer's disease has been observed. Numerous published studies indicate that the …

Microvascular endothelial dysfunction precedes, often by decades, the cognitive decline
associated with Alzheimer's disease. Hence, preservation of a healthy cerebrovascular …

Much evidence has been published which indicates that microvascular endothelial
dysfunction, due to cerebrovascular risk factors (eg, atherosclerosis, hypertension, obesity …

Neurodegenerative disorders including Alzheimer's, Parkinson's, and dementia are chronic
and advanced diseases that are associated with loss of neurons and other related …

Early changes in cerebrovascular hemodynamics and endothelial function can contribute to
altered cognitive function and systemic vascular stiffness later in life. Accordingly, vascular …

The blood-brain barrier (BBB) restricts the access of therapeutic agents to the brain,
complicating the treatment of neurological diseases, such as Alzheimer's disease (AD) …

Due to the complexity of Alzheimer's disease, multiple cellular types need to be targeted
simultaneously in order for a given therapy to demonstrate any major effectiveness …

Past published studies have already documented that, subsequent to the intravenous
injection of colloidal lipid nanocarriers, apolipoprotein (apo) AI is adsorbed from the blood …

By incorporating appropriate drug (s) into lipid (biobased) nanocarriers, one obtains a
combination therapeutic for dementia treatment that targets certain cell-surface scavenger …

Previous research has already shown that apolipoprotein (apo) AI is adsorbed from the
bloodstream onto the surface of certain colloidal lipid particles after the intravenous injection …